DT 200

Drug Profile

DT 200

Alternative Names: DT-200; G 100192; GLPG-0492; SARMs - Galapagos NV

Latest Information Update: 18 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ProSkelia
  • Developer Akashi Therapeutics; Galapagos NV
  • Class Small molecules
  • Mechanism of Action Selective androgen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Duchenne muscular dystrophy
  • Discontinued Cachexia

Most Recent Events

  • 15 Sep 2014 Preclinical trials in Duchenne muscular dystrophy in USA (PO)
  • 24 Jun 2014 DART Therapeutics is now called Akashi Therapeutics
  • 20 Mar 2013 DART Therapeutics acquires DT 200 from Galapagos NV
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top